Tampere University Hospital
- Address
- Medisiinarinkatu 3, 33521 Tampere, Finland
Tampere University Hospital - Hematologic Malignancies Research Center
Tampere University Hospital operates as a leading institution in hematologic malignancy research, with particular expertise in investigating novel therapeutic approaches for acute leukemias and myeloid disorders. The center focuses on advancing treatment protocols through rigorously designed clinical trials that evaluate promising combination therapies in newly diagnosed patients.
- Acute myeloid leukemia (AML) treatment optimization
- Myelodysplastic syndrome with excess blasts
- Venetoclax-based combination chemotherapy protocols
The hospital's research portfolio emphasizes Phase III randomized controlled trials that assess critical clinical endpoints including event-free survival and complete remission rates. Their work in evaluating induction and consolidation chemotherapy regimens contributes significantly to establishing evidence-based standards of care for patients with newly diagnosed acute myeloid leukemia and related hematologic conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Universitaetsklinikum Ulm AöR1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 107 other sites in Finland
Therapeutic Area Benchmark — Finland
Select a therapeutic area to compare against other sites in Finland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Finland
Market Share
Country: Finland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Tampere University Hospital
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Phase III Randomized, Placebo-Controlled Study of Venetoclax with Induction and Consolidation Chemotherapy in Newly Diagnosed AML or MDS-EB2 Patients | Universitaetsklinikum Ulm AöR | Phase III | Recruiting | Sep 2022 | — |
IMP list
lock Showing 1 of 3 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cytarabine | 1 | Unknown | 2022-09-13 | 2022-09-13 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.